Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 120 points (-0.7%) at 17,956 as of Thursday, June 4, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 740 issues advancing vs. 2,233 declining with 147 unchanged. The Health Services industry currently sits down 0.2% versus the S&P 500, which is down 0.5%. On the negative front, top decliners within the industry include Opko Health ( OPK), down 10.8%, Agilent Technologies ( A), down 1.6%, Smith & Nephew ( SNN), down 1.5%, Boston Scientific ( BSX), down 1.3% and Stryker Corporation ( SYK), down 0.8%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Bio-Reference Laboratories ( BRLI) is one of the companies pushing the Health Services industry higher today. As of noon trading, Bio-Reference Laboratories is up $9.35 (28.4%) to $42.31 on heavy volume. Thus far, 5.0 million shares of Bio-Reference Laboratories exchanged hands as compared to its average daily volume of 173,600 shares. The stock has ranged in price between $42.20-$46.74 after having opened the day at $45.65 as compared to the previous trading day's close of $32.96. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases in the United States. Bio-Reference Laboratories has a market cap of $904.1 million and is part of the health care sector. Shares are up 2.6% year-to-date as of the close of trading on Wednesday. Currently there are no analysts who rate Bio-Reference Laboratories a buy, 1 analyst rates it a sell, and 1 rates it a hold. TheStreet Ratings rates Bio-Reference Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Bio-Reference Laboratories Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.